Treating Metastatic HER2-negative Breast Cancer: Oncology Nursing Approaches to Improve Patient Quality of Life

The therapeutic landscape for HER2-neg metastatic breast cancer (HER2-neg MBC) is rapidly changing with the addition of antibody drug-conjugate (ADC) therapies.  As a result, clinicians are not confident or knowledgeable in applying emerging clinical data to the routine management of patients with MBC, including triple-negative breast cancer (TNBC).  Further, managing adverse events (AEs) that arise during treatment with these novel agents remains a substantial area of deficiency among oncology nurses. To overcome this barrier, CEC is sponsoring a series of live meetings at regional ONS chapter meetings to discuss the application of ADC therapy to HER2-neg MBC.

In this enduring CEC ONS Chapter installment, expert faculty will review emerging data on ADC use for HER2-neg MBC and share insights and strategies on the impact of AEs associated with ADC use and approaches to the management of AEs associated with ADCs in this patient population.

At the conclusion of this activity, learners will be able to better:

• Summarize the impact of AEs associated with ADC use on the health-related quality of life (HRQoL) of patients with HER2-neg MBC
• Differentiate patients with HER2-neg MBC who are at risk of higher-grade AEs when receiving ADCs
• Select optimal approaches to the management of AEs associated with ADC use by patients with HER2-neg MBC

Supported by an independent educational grant from Gilead Sciences, Inc.

Oncology nurse practitioners (NPs) and registered nurses (RNs) (academic and community)

It is the policy of CE Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CE Concepts, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Ms. Beaver reports the following financial relationships:

Speakers Bureau: Padcev: drug for urothelial cancer: Astellas Pharma Inc./Seagen

The following individuals have no financial relationships to disclose:

Margaret Wright, BSN, RN (Peer Reviewer)
Evan Luberger (Planning Committee)
David Modrak, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CE Concepts, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.